Research Compound
CJC-1295 W/ DAC
CJC-1295 with DAC is a synthetic peptide analog of GHRH conjugated with a Drug Affinity Complex, available as a lyophilized powder for laboratory research.
Select Size
5mg
SKU: CD5
Batch: 202601-01-CD
$37.99
Ships today if ordered by 4PM EST
Est. Arrival: 09/18/2026
Volume Discounts
Qty: 1 - 4$37.99 each
Qty: 5 - 9$34.19 each(save $3.80)
Qty: 10+$30.39 each(save $7.60)
Quantity:
1
For Research Use Only. This product is intended for laboratory and scientific research purposes only. It is not a drug or dietary supplement and is not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease.
99%+ Purity
COA Included
Fast Shipping
USA Based
Product Details
CJC-1295 with DAC consists of modified GHRH(1-29) conjugated to Drug Affinity Complex (DAC). DAC is a lysine linked to maleimidopropionic acid (MPA) enabling covalent albumin binding via Cys34 thiol.
Contains same four substitutions as no-DAC version (D-Ala2, Ala8, Leu15, Leu27). DAC addition significantly extends half-life through albumin conjugation. Soluble in sterile water or bacteriostatic water. Store at -20°C.
Disclaimer: For laboratory and research purposes only. Not intended for human consumption.
Frequently Asked Questions About CJC-1295 W/ DAC
Answers summarize published research and are provided for laboratory research purposes only.
CJC-1295 W/ DAC is a synthetic analog of growth hormone releasing hormone, or GHRH. It consists of modified GHRH(1-29), carrying the substitutions D-Ala2, Ala8, Leu15, and Leu27, conjugated to a Drug Affinity Complex. Research studies have examined CJC-1295 W/ DAC as a long acting GHRH analog in growth hormone axis research. Biotech Compounds supplies it as a lyophilized powder for laboratory research.
The Drug Affinity Complex, or DAC, is a lysine residue linked to maleimidopropionic acid, abbreviated MPA. Research studies have shown that the maleimide group forms a covalent bond with the free thiol on cysteine 34 of serum albumin. Researchers reported that this binding turns CJC-1295 W/ DAC into an albumin bound reservoir in circulation, which is the basis for its extended activity in experimental models.
In research studies, CJC-1295 W/ DAC has been observed to act at the GHRH receptor on pituitary cells in the same way as native GHRH. Published research reports that albumin binding through the DAC shields the peptide from enzymatic clearance, so the signal persists far longer than with unconjugated GHRH analogs. Researchers described sustained rather than pulsatile stimulation of growth hormone secretion in models exposed to CJC-1295 W/ DAC.
The primary research area for CJC-1295 W/ DAC is the growth hormone and IGF-1 axis. In clinical research, investigators reported that CJC-1295 W/ DAC was associated with sustained increases in growth hormone and IGF-1 levels lasting for days after a single exposure. Animal models and in vitro studies have also used CJC-1295 W/ DAC to examine prolonged GHRH receptor activation.
CJC-1295 W/ DAC was originally developed by a pharmaceutical company and advanced into phase 1 and phase 2 clinical trials as an investigational GHRH analog. Development was later discontinued, and CJC-1295 W/ DAC is not approved by the FDA or any other regulator. Published data therefore include human pharmacology reports alongside animal and in vitro work, but the compound remains investigational.
Both compounds share the same modified GHRH(1-29) sequence with four amino acid substitutions. CJC-1295 W/ DAC carries the Drug Affinity Complex that binds albumin, and research has reported a half-life of several days. CJC-1295 (no DAC) lacks albumin binding, and researchers reported a half-life of minutes. In experimental models the DAC form produces sustained elevation while the no DAC form produces short pulses.
Sermorelin is GHRH(1-29) with the native amino acid sequence, while CJC-1295 W/ DAC carries four stabilizing substitutions plus the albumin binding Drug Affinity Complex. Research studies have reported that Sermorelin is cleared quickly and produces a brief signal, whereas CJC-1295 W/ DAC has been observed to act over days. Researchers choose Sermorelin for short pulse studies and CJC-1295 W/ DAC for prolonged exposure designs.
CJC-1295 W/ DAC is supplied as a lyophilized powder and is soluble in sterile water or Bacteriostatic Water. In the laboratory, the diluent is added slowly down the inside wall of the vial, and the vial is swirled gently until the powder dissolves. The vial should never be shaken, since agitation can damage the peptide and the maleimide linker. Reconstitution volume is set by the experimental design.
Lyophilized CJC-1295 W/ DAC should be stored at -20 C in a dry, dark place. After reconstitution, CJC-1295 W/ DAC should be refrigerated at 2 to 8 C, protected from light, and used within a short window. Repeated freeze thaw cycles should be avoided. The reactive maleimide group in the DAC is a reason to keep reconstituted solutions cold and to prepare them close to the time of use.
CJC-1295 W/ DAC from Biotech Compounds is listed at 99 percent plus purity. Each lot is third party tested, and a Certificate of Analysis is available on the CJC-1295 W/ DAC product page so researchers can confirm identity and purity before use. Laboratories are encouraged to review the COA and keep it with their experimental records.
CJC-1295 W/ DAC has the molecular formula C165H271N47O46 and a molecular weight of approximately 3647.0 g/mol. The molecular weight is higher than that of CJC-1295 (no DAC) because the Drug Affinity Complex, a lysine linked to maleimidopropionic acid, adds mass to the 29 amino acid GHRH analog backbone.
No. CJC-1295 W/ DAC is sold strictly as a research material for laboratory research by qualified researchers and research organizations. Purchasers must be 21 or older. CJC-1295 W/ DAC is not a drug or dietary supplement, and it is not for human or animal consumption. Biotech Compounds supplies it for in vitro and preclinical investigation only.
You May Also Like
